{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-001517","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.146114+00:00","generated_at":"2026-05-26T04:26:32.456713+00:00","sec_items":["1.02","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"confidence":"high","headline":"GlycoMimetics loses China license for uproleselan; CEO, CFO, 5 directors depart","bullets":["Apollomics terminated the collaboration license for uproleselan and GMI-1687 in China, effective 90 days from Feb 19, 2025.","CEO Harout Semerjian and CFO Brian Hahn ceased employment on Feb 21, 2025; severance payments of $1,365,456 and $480,991 respectively.","Five directors (Goldberg, Jackson, King, Koenig, Semerjian) resigned Feb 21, 2025; no disagreement with company operations.","Semerjian consulting: $700/hr for 12 months; Hahn consulting: $15,000/month through change in control or Sep 30, 2025.","Company is pursuing a merger with Crescent Biopharma (Form S-4 filed)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-001517","json":"https://secwatch.observer/filing/0001558370-25-001517.json","markdown":"https://secwatch.observer/filing/0001558370-25-001517.md","text":"https://secwatch.observer/filing/0001558370-25-001517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/glyc-20250219x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:26:32.456713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"226bee0065","claim":"Rachel King resigned as Director at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm","confidence":0.95},{"claim_id":"290de6af05","claim":"Harout Semerjian resigned as Director at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"Mr. Semerjian also resigned from the Board of Directors effective as of February 21, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm","confidence":0.95},{"claim_id":"3e0859b4b4","claim":"Mark Goldberg resigned as Director at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm","confidence":0.95},{"claim_id":"55d17dab71","claim":"Scott Jackson resigned as Director at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm","confidence":0.95},{"claim_id":"816677156a","claim":"Brian Hahn departed as Chief Financial Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm","confidence":0.95},{"claim_id":"860c9512d0","claim":"Harout Semerjian departed as Chief Executive Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm","confidence":0.95},{"claim_id":"fdfccd119c","claim":"Scott Koenig resigned as Director at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837025001517/0001558370-25-001517-index.htm","confidence":0.95}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}